Nicotine as a potential neuroprotective agent for Parkinson's disease

Movement Disorders

Volumn 27, Issue 8, 2012, Pages 947-957

  Quik, Maryka ^a   Perez, Xiomara A ^a   Bordia, Tanuja ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Neuroprotection; Nicotine; Nicotinic; Nigrostriatal damage; Parkinson's disease

Indexed keywords

ACETYLCYSTEINE; BEE VENOM; BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR; CREATINE; DEFERIPRONE; ERYTHROPOIETIN; EXENDIN 4; FOLIC ACID; GANGLIOSIDE GM1; GLUTATHIONE; GPI 1485; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INOSINE; ISRADIPINE; MINOCYCLINE; MITOQUIDONE; NICOTINE; NICOTINE PATCH; NICOTINIC RECEPTOR ALPHA4BETA2; PIOGLITAZONE; PLACEBO; POLYPHENOL; PRELADENANT; RASAGILINE; SAFINAMIDE; UBIDECARENONE; UBIQUINONE;

BRAIN DAMAGE; BRAIN DEPTH STIMULATION; CIGARETTE SMOKING; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE MUTATION; HUMAN; INCIDENCE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; NICOTINE; NICOTINIC AGONISTS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; SMOKING; SUBSTANTIA NIGRA;

EID: 84864005036     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25028     Document Type: Review

References (130)

1. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011; 26: 1049-1055.
2. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011; 10: 377-393.
3. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord. 2011; 26: 1072-1082.
4. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci. 2009; 30: 41-47.
5. Wichmann T, DeLong MR, Guridi J, Obeso JA. Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord. 2011; 26: 1032-1041.
6. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord. 2011; 26: 1015-1021.
7. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med, 2010; 16: 653-661.
8. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol. 2011; 26: 547-555.
9. Sanyal J, Chakraborty DP, Sarkar B, et al. Environmental and familial risk factors of Parkinsons disease: case-control study. Can J Neurol. Sci. 2010; 37: 637-642.
10. Tanner CM. Advances in environmental epidemiology. Mov Disord. 2010; 25( Suppl 1): S58-S62.
11. Fahn S. Parkinson's disease: 10 years of progress, 1997-2007. Mov Disord. 2010; 25( Suppl 1): S2-S14.
12. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26( Suppl 1): S1-S58.
13. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron. 2010; 66: 646-661.
14. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs. 2010; 24: 177-192.
15. Olanow CW, McNaught K. Parkinson's disease, proteins, and prions: milestones. Mov Disord. 2011; 26: 1056-1071.
16. Cenci MA, Ohlin KE. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15( Suppl 4): S13-S17.
17. Jenner P. Functional models of Parkinson's disease: A valuable tool in the development of novel therapies. Ann Neurol. 2009; 64: S16-S29.
18. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011; 10: 1108-1118.
19. Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease. The state of the art. Prog Brain Res. 2010; 184: 53-87.
20. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord. 2011; 26: 993-1002.
21. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One. 2010; 5: e8762.
22. Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol. 2008; 15( Suppl 1): 5-13.
23. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem. 2009; 109: 1427-1439.
24. LeWitt PA. Neuroprotection for Parkinson's disease. J Neural Transm Suppl. 2006: 113-122.
25. Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol. 2007; 203: 512-520.
26. Reglodi D, Kiss P, Lubics A, Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des. 2011; 17: 962-972.
27. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol. 2008; 209: 82-88.
28. L' Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets. 2010; 9: 349-372.
29. von Bernhardi R, Tichauer JE, Eugenin J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J Neurochem. 2010; 112: 1099-1114.
30. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 2010; 31: 7-17.
31. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-397.
32. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007; 447: 1081-1086.
33. Nicoletti A, Pugliese P, Nicoletti G, et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov Disord. 2010; 25: 2387-2394.
34. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010; 183: 183-208.
35. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol. 1996; 144: 480-484.
36. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005; 58: 797-800.
37. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008; 65: 716-723.
38. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007; 166: 561-567.
39. Szabo N, Kincses ZT, Vecsei L. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol. 2011; 7: 441-455.
40. Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 2010; 20( Suppl 1): S205-S220.
41. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010; 74: 878-884.
42. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 1995; 45: 1041-1051.
43. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007; 64: 990-997.
44. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007; 68: 764-768.
45. O'Reilly EJ, McCullough ML, Chao A, et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord. 2005: 1383-1384.
46. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord. 2004; 19: 614-621.
47. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology. 2002; 58: 581-588.
48. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging. 2001; 18: 797-806.
49. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol. 2001; 50: 780-786.
50. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology. 1999; 52: 115-119.
51. Baron JA. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br Med Bull. 1996; 52: 58-73.
52. Castagnoli K, Murugesan T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology. 2004; 25: 279-291.
53. Castagnoli K, Petzer JB, Steyn SJ, van der Schyf CJ, Castagnoli NJr., Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration. Inflammopharmacology. 2003; 11: 183-188.
54. Castagnoli KP, Steyn SJ, Petzer JP, Van der Schyf CJ, Castagnoli NJr., Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chem Res Toxicol. 2001; 14: 523-527.
55. LeWitt PA, Taylor DC. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics. 2008; 5: 210-225.
56. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010; 92: 330-344.
57. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011; 10: 415-423.
58. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol. 2002; 53: 590-605.
59. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol. 2007; 74: 1235-1246.
60. * Nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev. 2011; 63: 938-966.
61. O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Target CNS Neurol Disord. 2002; 1: 399-411.
62. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci. 2008; 13: 492-504.
63. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol. 2007; 62: 588-596.
64. Costa G, Abin-Carriquiry JA, Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 2001; 888: 336-342.
65. Dajas F, Costa G, Abin-Carriquiry JA, McGregor R, Urbanavicius J. Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism. Funct Neurol. 2001; 16( Suppl 4): 113-123.
66. Huang LZ, Parameswaran N, Bordia T, Michael McIntosh J, Quik M. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem. 2009; 109: 826-837.
67. Parain K, Marchand V, Dumery B, Hirsch E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 2001; 890: 347-350.
68. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol. 2001; 132: 1650-1656.
69. Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J. 2011; 25: 2563-2573.
70. Visanji NP, O'Neill M J, Duty S. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology. 2006; 51: 506-516.
71. Quik M, Chen L, Parameswaran N, Xie X, Langston JW, McCallum SE. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned primates. J. Neurosci 2006; 26: 4681-4689.
72. Quik M, Parameswaran N, McCallum SE, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006; 98: 1866-1875.
73. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009; 89: 73-120.
74. Millar NS, Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology. 2009; 56: 237-246.
75. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol. 2009; 78: 677-685.
76. * receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci 2010; 30: 5311-5325.
77. Ward RJ, Lallemand F, de Witte P, Dexter DT. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: Potential targets for the development of new therapeutic agents. Prog Neurobiol. 2008; 85: 135-147.
78. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology. 2002; 23: 581-594.
79. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull. 2009; 32: 332-336.
80. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2002; 249( Suppl 3): III/1-5.
81. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
82. Braak H, Muller CM, Rub U, et al. Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl. 2006: 89-97.
83. Hosur V, Loring RH. alpha4beta2 nicotinic receptors partially mediate anti-inflammatory effects through Janus kinase 2-signal transducer and activator of transcription 3 but not calcium or cAMP signaling. Mol Pharmacol. 2011; 79: 167-174.
84. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004; 25: 317-324.
85. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm. 2007; 114: 135-147.
86. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004; 27: 561-568.
87. Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis. 2011; 24( Suppl 2): 95-109.
88. Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res. 2000; 113: 21-34.
89. Massey KA, Zago WM, Berg DK. BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons. Mol Cell Neurosci. 2006; 33: 381-388.
90. Zhou X, Nai Q, Chen M, Dittus JD, Howard MJ, Margiotta JF. Brain-derived neurotrophic factor and trkB signaling in parasympathetic neurons: relevance to regulating alpha7-containing nicotinic receptors and synaptic function. J. Neurosci 2004; 24: 4340-4350.
91. Formaggio E, Fazzini F, Dalfini AC, et al. Nicotine increases the expression of neurotrophin receptor tyrosine kinase receptor A in basal forebrain cholinergic neurons. Neuroscience. 2010; 166: 580-589.
92. Park HJ, Lee PH, Ahn YW, et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci. 2007; 26: 79-89.
93. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. 2009; 182: 1730-1739.
94. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med. 2009; 265: 663-679.
95. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology. 2003; 44: 642-652.
96. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1998; 358: 351-359.
97. Newman MB, Arendash GW, Shytle RD, Bickford PC, Tighe T, Sanberg PR. Nicotine's oxidative and antioxidant properties in CNS. Life Sci. 2002; 71: 2807-2820.
98. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Lopez-Real AM, Labandeira-Garcia JL. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol. 2002; 64: 125-135.
99. Xie YX, Bezard E, Zhao BL. Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. J Biol Chem. 2005; 280: 32405-32412.
100. Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther. 2008; 327: 239-247.
101. Bordia T, Campos C, McIntosh JM, Quik M. Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther. 2010; 333: 929-938.
102. Huang L, Grady SR, Quik M. Nicotine reduces L-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors. J Pharmacol Exp Ther. 2011; 338: 932-941.
103. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord. 1998; 13: 637-642.
104. Domino EF, Ni L, Zhang H. Nicotine alone and in combination with l-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys. Exp Neurol. 1999; 158: 414-421.
105. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol. Sci. 1993; 117: 28-32.
106. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl). 1994; 116: 117-119.
107. Clemens P, Baron JA, Coffey D, Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology (Berl). 1995; 117: 253-256.
108. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord. 1999; 14: 1011-1013.
109. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn. 2000; 43: 274-282.
110. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology. 2001; 57: 1032-1035.
111. Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol. 2007; 14: 1313-1316.
112. Shoulson I. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology. 2006; 66: 408-410.
113. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 31-39.
114. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord. 2008; 23: 1641-1652.
115. Thiriez C, Villafane G, Grapin F, Fenelon G, Remy P, Cesaro P. Can nicotine be used medicinally in Parkinson's disease? Expert Rev Clin Pharmacol. 2011; 4: 429-436.
116. Benowitz NL. Nicotine addiction. N Engl J Med. 2010; 362: 2295-2303.
117. De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci. 2010; 34: 105-130.
118. Dwoskin LP, Bardo MT. Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse. Neuropsychopharmacology. 2009; 34: 244-246.
119. Paolini M, De Biasi M. Mechanistic insights into nicotine withdrawal. Biochem Pharmacol. 2011; 82: 996-1007.
120. Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs. 2011; 25: 371-382.
121. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord. 2008; 23: 1799-1807.
122. O'sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord. 2008; 23: 101-106.
123. Changeux JP. Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol. 2010; 50: 1-38.
124. Sarter M, Parikh V, Howe WM. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol. 2009; 78: 658-667.
125. Poorthuis RB, Goriounova NA, Couey JJ, Mansvelder HD. Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. Biochem Pharmacol. 2009; 78: 668-676.
126. McIntosh JM, Absalom N, Chebib M, Elgoyhen AB, Vincler M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem Pharmacol. 2009; 78: 693-702.
127. Buckingham SD, Jones AK, Brown LA, Sattelle DB. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev. 2009; 61: 39-61.
128. Bacher I, Wu B, Shytle DR, George TP. Mecamylamine -a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin Pharmacother. 2009; 10: 2709-2721.
129. Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci. 2010; 31: 580-586.
130. Philip NS, Carpenter LL, Tyrka AR, Price LH. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl). 2010; 212: 1-12.